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Cardiac stem/progenitors are being used in the clinic to treat patients with a range of cardiac pathologies.
However, improvements in heart function following treatment have been reported to be variable, with some
showing no response. This discrepancy in response remains unresolved. Mesenchymal stem cells (MSCs) have
been highlighted as a regenerative tool as these cells display both immunomodulatory and proregenerative
activities. The purpose of this study was to derive a cardiac MSC population to provide an alternative/support to
current therapies. We derived human cardiac-mesenchymal stem cell-like cells (CMSCLC), so named as they
share some MSC characteristics. However, CMSCLC lack the MSC trilineage differentiation capacity, being
capable of only rare adipogenic differentiation and demonstrating low/no osteogenic or chondrogenic potential,
a phenotype that may have advantages following transplantation. Furthermore, CMSCLC expressed low levels
of p16, high levels of MHCI, and low levels of MHCII. A lack of senescent cells would also be advantageous
for cells to be used therapeutically, as would the ability to modulate the immune response. Crucially, CMSCLC
display a transcriptional profile that includes genes associated with cardioprotective/cardiobeneficial effects.
CMSCLC are also secretory and multipotent, giving rise to cardiomyocytes and endothelial cells. Our findings
support CMSCLC as a novel cell population suitable for use for transplantation.
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Introduction
Cellular strategies using bone marrow-derived cellsor autologous cardiac-derived cells have translated into
the clinical setting as potential therapies for the treatment of
patients with heart failure [1–3]. Although these trials have
demonstrated some benefits of these therapies, they are also not
without limitations, with reports of only modest improvements
in cardiac function in some patients and no improvements in
others. The mechanisms behind the improvements that have
occurred remain unclear, it has been postulated that these
transplanted cells either contribute to regeneration themselves
giving rise to new cardiomyocytes or that they secrete paracrine
factors to support native cardiac cells, spared by injury, al-
lowing these cells to recover and promote some level of cardiac
regeneration. Regardless of the mechanism, a better under-
standing of these cells may lead to improvement in cardiac
regeneration. However, the choice of the most appropriate
cell population for this application is yet to be determined.
Mesenchymal stem cells (MSCs) have been selected as a useful
cell population for tissue regeneration as they have been re-
ported to be safe, have immunomodulatory effects, and to se-
crete proregenerative factors [4–8]. Human subendocardial
MSCs have been derived; this cell population was capable of
expansion in vitro, expressed markers normally expressed by
MSCs, and was capable of multilineage differentiation to os-
teoblasts, adipocytes, and chondrocytes. Moreover, these cells
express cardiac transcription factors while lacking expression
of markers associated with mature cardiomyocytes [9].
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In this study, we aimed to determine if we could isolate a
cardiac cell population using tissue that is normally dis-
carded as surgical waste (and therefore not necessitating any
additional invasive procedures), from which we could derive
cells that were MSCs or had MSC-like qualities and might
therefore make them a more optimal tool to study cardiac
regeneration. We opted for specimens of right atrial ap-
pendage (RAA), which are excised during coronary artery
bypass surgery. RAA has previously been described as having
characteristics of both atrial and ventricular tissue [10] and
has been used as a source of stem cells used in a clinical trial
[1]. We isolated a stem cell population that we have termed
cardiac-derived mesenchymal stem cell-like cells (CMSCLC)
and compared these with cardiosphere-cardiac-derived cells
(CS-CDCs) (also RAA derived) and to bone marrow-derived
MSCs (BM-MSCs). We demonstrate that while these
CMSCLC are similar to other reported MSC populations,
for example, have an MSC-like morphology, they also differ
as they are largely incapable of the trilineage differentiation
normally displayed by MSCs. Some CMSCLC could be
made to differentiate into cells of the adipogenic lineage, and
while displaying the morphology of osteoblasts under osteo-
genic culture conditions, contributed to no or negligible
matrix mineralization, and under chondrogenic culture con-
ditions did not undergo chondrogenesis. This was in contrast
to CS-CDCs that differentiated readily to the osteogenic
lineage, while also only displaying a low level of adipogenic
lineage differentiation potential. However, both CMSCLC
and CS-CDCs under in vitro cardiac differentiation condi-
tions displayed morphological changes indicative of a more
mature cardiac lineage cell, while the CMSCLC also showed
early striation formation. In addition, we show that some
CMSCLC express the senescence marker p16. We also
undertook transcriptional analysis of single CMSCLC from
three individual human heart tissue donors and showed that
they expressed at varying levels; genes associated with
pluripotency, proliferation, migration, differentiation, endo-
thelial cells, cardiogenesis, and cardioprotective factors. These
data provide further support for results obtained using a range
of other techniques used in this study. Taken together, our data
suggest that these CMSCLC differ from CS-CDCs. CMSCLC
have a more limited ability to differentiate to noncardiac cell
lineages than CS-CDCs, but can be expanded in vitro while
retaining cardiac and some MSC characteristics.
Materials and Methods
Study approval
All studies were performed according to the amended
Declaration of Helsinki. All cardiac tissue samples were
collected from consenting patients undergoing cardiac sur-
gery at the James Cook University Hospital, Middlesbrough,
United Kingdom. Approval for collection and use of tissue
was given by the local ethics committee under REC number
UKCRN ID: 20120092.
Derivation and culture of CMSCLC
RAA [from five patients, three males—ages 62 (patient
number 1,179), 66 (patient number 1,201), and 73 (patient
number 1,201) and two females ages 66 (patient number
1,114) and 78 (patient number 1,132)], all undergoing cor-
onary artery bypass surgery), was washed and chopped
followed by digestion for 45min in 0.01% (wt/vol) pronase
(Calbiochem), during which the tissue suspension was ro-
tated on an MACS rotator (Miltenyi) at 37C and then tissue
was dissociated using a gentleMACS dissociator (Miltenyi).
The resulting cell suspension was then filtered through a
70 mm cell strainer (BD). Cardiac cell suspensions were
made up to a total of 6mL with MSC medium (aMEM 10%
(vol/vol), fetal bovine serum 1% (vol/vol), GlutaMAX
5 ng/mL, and FGF2, (Peprotech), seeded into T-25 culture
flasks, and cultured at 5% CO2, 5% O2. The culture medium
was removed 72 h postseeding and nonadherent cells were
removed by rinsing three times with Dulbecco’s phosphate
buffered saline (DPBS). Fresh culture medium was added
and further medium changes were performed every three
days thereafter. Colony-forming unit fibroblasts where de-
fined as colonies if they contained 50 or more cells. colony
forming units (CFUs) were observed*15 days postseeding,
and these ranged from 8 to 11 CFUs per CMSCLC culture
and 18 CFUs for bone marrow (Fig. 1). All colonies from
each individual donor were expanded as a pool until con-
fluent. On confluence, cell cultures were expanded by pas-
sage at a ratio of 1:3 using TrypLE Express.
Cell population doublings of CMSCLC
Cell population doubling of CMSCLC per day were cal-
culated over three cell passages; the equation to calculate
this is provided in the Statistical Analysis section and based
on Ref. [11].
Derivation and culture of cardiac-derived
cells from cardiospheres
Cardiospheres were derived using methods described pre-
viously [12]. In brief, RAA (from three patients, one female
age 84 and two males ages 59 and 65, all undergoing coro-
nary artery bypass surgery) were minced into small <1mm3
fragments in trypsin and transferred to fibronectin-coated
plates in DMEM with 20% serum containing 0.1mmol/l 2-
mercaptoethanol (GIBCO). Following culture for 10 days,
nonadherent-phase bright cells were harvested and cultured
on poly-D-lysine in cardiosphere growing media. Several
days later, cells that remained adherent to the poly-D-lysine-
coated dishes were discarded, while detached cardiospheres
were harvested and expanded as a monolayer of CDCs on
fibronectin-coated plates.
Derivation and culture of BM-MSCs
Bonemarrowmononuclear cells (BMMNCs)were purchased
from Lonza (27-year-old male donor). BMMNCs were re-
suspended in MSC medium, seeded at a density of 1.25·107
cells/T-75 flask and cultured at 5% CO2, 5% O2. The culture
medium was removed 72h postseeding and nonadherent cells
were removed by rinsing three times with DPBS. Fresh culture
medium was added and further medium changes were per-
formed every 3days thereafter.On confluence, cell cultureswere
expanded by passage at a ratio of 1:3 using TrypLE Express.
Immunophenotyping of MSCs
Cardiac cells were detached from tissue culture plastic
using TrypLE Express and resuspended in flow cytometry
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(FACS) buffer to a cell density of 1· 106 cells/mL. Aliquots
of 200 mL were transferred to 1.5mL microfuge tubes and
incubated at 4C for 1 h with 5 mg/mL of primary antibody
(CD44, CD90, CD105, CD106, CD146, CD166, CD19,
CD45, or IgG isotype control). Primary antibodies and IgG
control were taken from the Human Multipotent Mesench-
ymal Stromal Cell Marker Antibody Panel kit (R&D Sys-
tems). Cells were rinsed with phosphate buffered saline and
then resuspended in FACS buffer with donkey anti-mouse
secondary antibody conjugated to Alexa Flour 488 diluted
1:250 (Invitrogen). Cells were labeled with directly conjugated
primary antibodies raised against MHC class I and MHC class
II antigens (HLA-ABC-FITC, 5mL of stock reagent in 200mL
of cell suspension, Beckman Coulter; PE mouse antihuman
FIG. 1. Morphology of different primary
cells in culture. Representative brightfield
images of cells in vitro at passage 3. (A)
BM-derived MSCs, (B–D) show images
from three different patient-derived cul-
tures of CMSCLC. Brightfield image
showing morphology of human CDCs (E)
Brightfield image of CMSCLC CFU (F).
All scale bars=100mm. CMSCLC cultures
derived from three different patient tissue
samples were assessed for their ability to
form CFUs under standard MSC culture
conditions, and BM was also assessed for
CFU formation ability (G). The number of
CFUs formed per culture at passage 1 is
represented graphically. MSCs, mesenchy-
mal stem cells; CMSCLC, cardiac-derived
mesenchymal stem cell-like cells; BM,
bone marrow. Color images are available
online.
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HLA-DR, 5mL of stock reagent in 200mL of cell suspension,
BD) and c-kit (5mg/mL of PE-conjugated primary antibody;
BD). Controls where unstained CDC and CMSCLC from the
same cell preparations. Analysis was done using FACSCanto
II (BD) with a 488 laser and 530/30 emission filter, and data
analysis collated using FACS DiVa software.
Analysis of platelet derived growth factor-alpha
expression by CMSCLC
Cells were prepared and analyzed as for immunopheno-
typing. A primary antibody used was 5 mg/mL of anti-human
platelet derived growth factor (PDGFR)-alpha (R&D sys-
tems, MAB322) and secondary was donkey anti-mouse
secondary antibody conjugated to Alexa Flour 488 diluted
1:250 (Invitrogen).
Chondrogenic differentiation of cell populations
Chondrogenic differentiation of cell populations was per-
formed as previously described [13], with slight modification.
Briefly, cells were collected by enzymatic detachment from
tissue culture plastic and centrifugation at 700g for 3min.
Cells were resuspended in chondrogenic medium at a cell
density of 5· 105 cells/mL. Aliquots of 1mL volume were
dispensed into 15mL conical tubes and cell aggregates formed
by centrifugation at 700g for 3min. The caps were loosened to
allow for gas exchange and the cultures incubated at 5% CO2,
5% O2 for 14 days with medium changes every 2 days.
Osteogenic differentiation of cell populations
Osteogenic differentiation of cell populations was per-
formed as previously described [14]. Briefly, cells were
seeded in MSC medium into 12-well tissue culture plates at
a density of 2.5 · 103 cells/cm2. Twenty-four hours post-
seeding, the medium was replaced with osteogenic medium.
Cultures were maintained for 28 days at 5% CO2, 5% O2
with medium changes performed every 3–4 days.
Adipogenic differentiation of cell populations
Adipogenic differentiation of cell populations was per-
formed using the StemPro Adipogenesis Differentiation
Kit (Gibco), as per the manufacturer’s instructions; cultures
were maintained under standard oxygen conditions for a
total of 21 days.
Histological evaluation of differentiated
cell populations
Adipogenic cultures were evaluated by phase-contrast mi-
croscopy and adipogenic cells identified as cells with promi-
nent clusters of cytoplasmic lipid vesicles at 21 days for
cardiac cells, these were then stained with oil red O. Adipo-
genic cultures were incubated for 30min at room temperature
with oil red O (stock solution of 30% [vol/vol] oil red O in
isopropanol diluted to 60% (vol/vol) in ddH2O). Excess oil red
O solution was removed and the cultures rinsed with ddH2O.
Osteogenic cultures were evaluated for matrix mineralization
by alizarin red staining. Osteogenic cultures were incubated
for 2 h at room temperature in 2% (wt/vol) alizarin red (pH 4.3
with 10% [vol/vol] ammonium hydroxide). Excess alizarin
red solution was removed and the cultures rinsed extensively
with DPBS to remove background staining. Chondrogenic cell
aggregates were embedded in optimal cutting temperature
compound cryopreservation medium and frozen on dry ice.
Cryosections (7mm) were cut onto slides for histological
analysis of cartilage tissue formation. For safranin O staining,
cell pellet sections were stained with Harris’ hematoxylin for
4min, destained in acid alcohol (1% vol/vol HCl, 70% vol/
vol) for 10 s, and rinsed in deionized water. Sections were
counterstained with 0.02% aqueous fast green FCF for 3min,
rinsed in 1% (vol/vol) acetic acid, and then stained with 0.1%
aqueous safranin O for 5min. The slides were rinsed, dehy-
drated, and mounted using DePeX mounting medium.
Cardiac differentiation of cell populations
CS-CDCs and CMSCLC were seeded into 12-well tissue
culture plates at a density of 2.5 · 103cells/cm2 and placed
under their respective culture conditions. After 3 days, the
culture medium was replaced with cardiac differentiation
medium (Cellutions) and this in turn was replaced every
4 days. After 7 days in cardiac differentiation medium, the
differentiating CMSCLC cultures were transferred to incu-
bation at 5% CO2, 22% O2 for a further 14 days of culture.
Endothelial cell differentiation of CMSCLC
CMSCLC were derived as described above and then
cultured in Endothelial Cell Growth Medium 2 (PromoCell)
for 9 days under standard oxygen conditions, with medium
being replaced every 3 days.
Immunocytochemistry
Cardiac differentiated cells grown either on coverslips or in
chamber slides were harvested after 2 or 3 weeks in cardiac
differentiation media, rinsed with DPBS, and fixed in cold
methanol at -20C for 20min. Primary antibodies used were
cardiac troponin C 1:200 (Ab30807; Abcam), NXK2.5 1:200
(Ab35842; Abcam), alpha tropomyosin 1:200 (GTX113857;
GeneTex), and cardiac actin 1:200 (GTX101876; GeneTex).
The secondary antibodies used were donkey anti-goat AF488
(A-11055; Invitrogen), donkey anti-rabbit AF594 (ab150076;
Invitrogen), and donkey anti-rabbit AF488 (A11008; Invitro-
gen). Negative controls were sections incubated as for primary
staining but without the inclusion of primary antibodies. As a
positive control, cells of the AC10 cell line (derived from
adult human ventricular cardiomyocytes) [15] were also
stained with the aforementioned antibodies. For confocal Z-
stack imaging, a Nikon Eclipse Ti was used running NIS
Elements AR 4.20.02 software.
Endothelial cell differentiation cells were grown in cham-
ber slides for 9 days, medium removed, and cells fixed in
ethanol for 10min. Cells were immunostained for CD34
(1:250; M7165; DakoCytomation) using an avidin/biotin/
peroxidase technique (Vectastain Elite ABC kit; Vector La-
boratories) and the reaction developed for 1–2min with 3,3¢-
diaminobenzidine (DAB; Sigma) containing 0.01% H2O2 to
give a brown reaction product. Sections were lightly coun-
terstained with Mayer’s hematoxylin for 30 s, dehydrated,
cleared in xylene, and mounted with DPX synthetic resin.
CMSCLC for senescence analysis at passage 3 were
maintained under standard MSC culture conditions in
chamber slides for 24 h and then fixed. Primary antibody
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used was p16 1:50 ( J0411; Santa Cruz), and the secondary
was donkey anti-rabbit IgG (H+L), Alexa Fluor 488 (A-
21206; Thermo Fisher) (1/1,000). Under · 20 magnifica-
tion, 5 distinct fields of cells were imaged using an Axio
imager 2 microscope (Zeiss) and the percentage of posi-
tive p16 expressing cells determined from these images.
ICC images to show p16 were obtained using a confocal
Nikon Eclipse Ti using NIS Elements AR 4.20.02 software
as mentioned above.
In vitro protein expression quantification
Following staining with NKX2.5 and troponin C anti-
bodies, cultures were imaged at random locations (n > 5).
Using ImageJ software (ImageJ; U.S. National Institutes of
Health; http://rsbweb.nih.gov/ij/), total cell numbers were
counted based on DAPI-stained nuclei. The percentage of
positive cells for each protein was calculated based on the
number of cells labeled with the specific antibody as a
percentage of the total cell numbers. All quantification was
performed in a blinded manner.
Polymerase chain reaction
Polymerase chain reaction (PCR)was performed as described
previously [16], PCR was run for 25 and 35 cycles to ascertain
that comparisons of expression were made at the exponential
phase and not once cDNA amplification had plateaued, data are
shown for 35 cycles. The primer sequences used were as fol-
lows: MEF2C forward: CGAGATACCCACAACACACG,
reverse: CGCTTGACTGAGGGACTTTC; GATA4 forward:
TCCCTCTTCCCTCCTCAAAT, reverse: TCAGCGTGTAA
AGGCATCTG; and b-actin forward: GCGGGAAATCGTGC
GTGAC, reverse: GGAAGGAAGGCTGGAAGAG.
ELISA
Cell culture supernatants (control was MSC media only)
from CMSCLC at day 14 and 17 of culture were analyzed
for IL-10, VEGF, FGF2, and TGFb1 secretion by ELISA,
according to the manufacturer’s instructions (IL-10, VEGF,
FGF2, TGFb1 DuoSet; R&D).
Single-cell capture
Single cells were captured and the loci of interest pre-
amplified using the C1 system (Fluidigm, software version
2.2.1) following the manufacturer’s protocol. Cells were par-
titioned using a 10–17mm C1 Single-Cell Preamp integrated
fluidic circuit (IFC) (PN 100-5479; Fluidigm). IFC priming,
cell loading and lysis, reverse transcription, and preamplifica-
tion were then carried out using reagents from the following
kits: C1 Single-Cell Auto Prep Reagent Kit (PN 100-5139;
Fluidigm), Ambion Single Cell-to-CT qRT-PCR Kit (4458237;
Thermo Fisher Scientific), and 20X TaqMan Gene Expression
primers (Thermo Fisher Scientific). Amplicons were trans-
ferred from the IFC to a 96-well plate and stored at -20C.
Single-cell gene expression analysis
Single cell gene expression analysis was carried out using
the BioMark HD system and IFC Controller HX (Fluidigm)
as per the manufacturer’s instructions. Gene expression
analysis was carried out using Dynamic Array Flex Six
Gene Expression IFCs (Fluidigm). Assays were run using
reagents from the following kits: Flex Six Gene Expression
Reagent Kit (Fluidigm), 20X TaqMan Gene Expression
primers (Thermo Fisher Scientific), and TaqMan Fast Ad-
vanced Master Mix (Thermo Fisher Scientific). TaqMan
primers used are listed in Supplementary Table S1.
Analysis of single-cell data
CT values were calculated using the Fluidigm Real-time
Analysis software. The remainder of the analysis was car-
ried out using data analysis primarily in R (version 3.4.1)
and the expression values extracted using SINGuLAR
Analysis Toolset v3.6.2. Low-quality cells were excluded
from the analysis if total expression per cell was less than
250, or if the number of detected genes per cell was less than
10. The filtered data were normalized using the compute-
SumFactors from the scran R package. The remainder of the
analysis was carried out using R core functions.
Statistical analysis
Cell population doubling of CMSCLC per day was cal-
culated over three cell passages using the following equation
[17]: population doublings per day = ln N/N0 x t-1. Where
N0 = number of cells seeded, N = number of cells counted at
passage, and t-1 = number of days to passage. The percent-
age of p16 expressing cells was determined using SPSS box
plot analysis. Excel 2013 was used to generate bar chart for
single-cell data.
Results
Morphology, CFU forming potential,
and doubling time of CMSCLC
CMSCLC were examined to determine if they had MSC-
like characteristics when cultured under standard MSC
culture conditions. At passage 3, BM-MSCs were plastic
adherent and displayed a distinct fibroblast-like morphology
(Fig. 1A), and CMSCLC also displayed these characteristics
at passage 3 (Fig. 1B–D). The morphology of CS-CDCs is
also shown as a comparison with the CMSCLC (1E). Col-
ony forming potential is a recognized stem cell character-
istic, an example of a CFU is shown (Fig. 1F). CMSCLC
from three different patient-derived cultures readily formed
similar numbers of CFUs around day 15 postseeding into
culture (Fig. 1G) as control BM-MSCs were also used and
formed CFUs at day 7 postseeding in vitro, CFUs were
counted at day 15 (Fig. 1G). Cell doubling rates of
CMSCLC were also determined for all three patient-derived
cell cultures and no significant difference in doubling rates
was observed (Supplementary Fig. S1).
Phenotyping of CMSCLC
CDCs and CMSCLC were screened for expression of cell
surface antigens known to be expressed by MSCs. Both cell
populations expressed CD44, CD105, and CD166, but the
CDCs express all these markers at much lower levels than
the CMSCLC (Fig. 2), while both expressed low levels of
the hematopoietic lineage markers CD19 and CD45 (Fig. 2).
Controls included IgG isotype control and unstained CDCs
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and CMSCLC (Fig. 2). CMSCLC were also tested for the
expression of MHC I and II. Representative images of
the data generated are shown (Fig. 3A), demonstrating that
the majority of cells expressed MHC I (98%) and lacked
expression of MHC II (0.4%). Controls included IgG isotype
control-stained and unstained CMSCLC (data not shown).
Three different patient-derived CMSCLC cultures were
analyzed for MHC expression and the percentages of posi-
tive cells per culture are shown (Fig. 3B). CMSCLC were
also examined for expression of c-kit, and this analysis re-
vealed the presence of c-kit expression in only a rare sub-
population of cells (0.5%–2.6%) (Fig. 3C and Table).
FIG. 2. Immunophenotyp-
ing of CS-CDCs and
CMSCLC. Representative im-
ages of FACS histograms
showing results of immuno-
phenotyping of CDCs (n=3)
and CMSCLC (n=3) using
cell surface antigens of both
hematopoietic lineage-com-
mitted cells (CD45 and CD19)
and those known to be ex-
pressed by MSCs (CD44,
CD105, CD166). Controls are
isotype control and unstained
cells for both cell popula-





6 OLDERSHAW ET AL.
Controls were CMSCLC stained with IgG isotype con-
trol only and unstained cells (data not shown). In addition
to immunophenotyping, the CMSCLC they were also im-
munostained (after 9 days in culture) for the expression of
CD34. Cells from the same donor-derived CMSCLC line
cultured under normal CMSCLC culture conditions showed
no/low CD34 expression, while cells cultured under endo-
thelial cell differentiation conditions showed increased ex-
pression of CD34 (Fig. 3D). We also examined CMSCLC
for expression of PDGFR-alpha and showed that some cells
express this marker (Supplementary Fig. S2).
Secretion of IL-10, VEGF, FGF2,
and TGFb1 by CMSCLC
To determine if CMSCLC secreted IL-10, VEGF, FGF2,
and TGFb1, CMSCLC were cultured under normal CMSCLC
conditions as described above and media were collected at day
14 and 17 of culture. In all cases, there was an increase in fold
expression when compared with control media. After 14 days
of culture, there was a 1.3-fold increase in IL-10 secretion, but
by day 17, there was a 4.5-fold increase in IL-10 secretion.
For VEGF at day 14, there was a 13.5-fold increase in VEGF
secretion, which dropped to an 11.7-fold increase at day 17
compared with control, whereas for FGF2, at both day 14 and
17 there was an 8.9-fold increase compared with control. For
TGFb1, there was a 1.5-fold increase at both time points
compared with control (Supplementary Fig. S3A). In all cases
except for IL10 at day 14, the increase in expression compared
with control was significant (Supplementary Fig. S3B).
Osteogenic, adipogenic, and chondrogenic
differentiation potential of CMSCLC
To determine the differentiation potential to the above-
mentioned lineages, CMSCLC, CDCs, and BM-MSCs were
cultured under the appropriate lineage differentiation con-
ditions. Cultures were examined microscopically for mor-
phological changes, both CDCs (Fig. 4A) and CMSCLC
(Fig. 4B) underwent morphological changes when cultured
for 28 days under osteogenic culture conditions, but when
stained for matrix mineralization using alizarin red only, the
FIG. 3. FACS analysis for
expression of MHCs and c-kit,
and IHC analysis for CD34
expression, by CMSCLC. (A)
Representative images of
FACS histograms showing
expression levels of MHC I
and MHC II by CMSCLC.
(B) Table showing percent-
age of cells expressing
MHCI and MHCII in three
different patient-derived
CMSCLC cultures. (C) Rep-
resentative image of FACS
histogram showing expression
level of c-kit in CMSCLC and
table showing percentage of
cells expressing c-kit in three
different patient-derived
CMSCLC cultures. (D) Cells
from the same patient-
derived CMSCLC line were
cultured for 9 days under
normal CMSCLC culture
conditions (Control) and under
endothelial cell (EC) culture
conditions (EC differentiation
media) and were analyzed
for the expression of CD34.




bars = 100mm. All cultures
were examined at passage 3.
IHC, immunohistochemistry.
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CDC cultures stained (Fig. 4C), whereas the CMSCLC
showed low/no positive staining (Fig. 4D). Adipogenic
differentiation was determined by the presence of cells with
prominent clusters of cytoplasmic lipid vesicles that stained
positively with oil red O after 21 days in culture (Fig. 4E, F).
When cultured under chondrogenic culture conditions at
14 days, the CDCs (Fig. 4G) and CMSCLC (Fig. 4H)
formed aggregates, but when evaluated histologically failed
to stain with safranin O and had not undergone chondro-
genic differentiation. BM-MSCs cultured under the same
trilineage differentiation culture conditions provided a
control and successfully differentiated to the osteogenic
FIG. 4. Characterization of trilineage differentiation potential of CDCs and CMSCLC at passage 3. Representative
brightfield images, from three different patient tissue samples of (A) CDC and (B) CMSCLC after 28 days in osteogenic
culture conditions and before alizarin red staining, demonstrate cellular proliferation and matrix deposition. Images of cells
from the same samples but after being stained with alizarin red staining reveal mineralization of osteoid matrix within
osteogenic cultures differentiated from CDCs (C), whereas (D) there is no mineralization of culture matrix when CMSCLC
were differentiated. Images of CDCs (E) and CMSCLC (F) after 21 days under adipogenic culture conditions stained with
oil red O. Note the presence of red stained cells in both cultures. Images of cryosections of cell aggregates formed under
prochondrogenic culture conditions after 14 days and after staining with safranin O (counterstained with hematoxylin and
fast green) for CDCs (G) and CMSCLC (H). Note that while cell aggregates formed for both CDCs and CMSCLC,
chondrogenesis did not occur as evidenced by the absence of safranin O staining for sulfated glycosaminoglycans. His-
tological evaluation of cell aggregates shows lack of extracellular matrix deposition between cells and hence weak tissue
structure. All scale bars = 100 mm. BM-MSCs are shown after culture using the same differentiation protocols as for CDCs
and CMSCLC and stained with alizarin red (I), oil red O (J), and safranin O (K). Note BM-MSCs can differentiate to all
three lineages. Scale bars for (I, J)= 100 mm. Scale bar for (K)= 400mm. BM-MSCs, bone marrow-derived MSCs. Color
images are available online.
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lineage and displayed matrix mineralization as indicated by
alizarin red staining (4I), the adipogenic lineage as indicated
by oil red O staining of cells containing cytoplasmic lipid
vesicles (4J), and to the chondrogenic lineage as shown by
staining of aggregates with safranin O (4K).
Expression of p16 by CMSCLC
To establish if the level of senescence was higher in some
patients’ CMSCLC than others, we compared the level of
senescence from CMSCLC at passage 3 from three different
patients. The cultures were stained using p16 antisera. A
representative image of p16-stained cells in a CMSCLC
culture is shown (Fig. 5A). All cultures contained low per-
centages of p16 expressing cells (Fig. 5B).
Cardiac differentiation potential of CMSCLC
To determine the ability of CMSCLC to differentiate to a
more mature cardiac lineage, cells were cultured under cardiac
differentiation conditions; after 2 weeks, the cells were stained
for cardiac troponin I and NXK2.5 expression. CDCs have a
previously demonstrated cardiogenic potential and were used
as a positive control, being cultured under the same cardiac
differentiation conditions for the same length of time. For both
the CDCs (Fig. 6A) and CMSCLCs (Fig. 6B) for all cultures
examined, troponin C expressing cells with a flattened, spread,
and straight-edged morphology were present. While in all of
CDC cultures and in one CMSCLC culture, some cells were
present that expressed nuclear NKX2.5. Representative im-
ages of NKX2.5-positive cells are shown in CDC-derived
cultures (Fig. 6C) and from the CMSCLC culture (Fig. 6D).
The morphology of these cells differed from those shown
(Fig. 6A, B), as these cells had a more primitive rounded
morphology. To further demonstrate cardiomyocyte differen-
tiation, CMSCLC were differentiated for 3 weeks, labeled for
troponin C, cardiac actin, or the striated muscle-specific iso-
form of tropomyosin, a-tropomyosin, and imaged using Z-
stack confocal microscopy. Maximum-intensity z-stack pro-
jections demonstrated filamentous staining for all proteins
(Fig. 6E–H). In addition, maximum intensity volume projec-
tion of alpha-tropomyosin labeling clearly demonstrates the
striated phenotype of these differentiating cells (Fig. 6H, Hi).
Note the absence of staining in negative controls (Supple-
mentary Fig. S4A–C) and staining with all antibodies of cells
of the AC10 cell line (Supplementary Fig. S4D). Analysis for
percentage of cells expressing NKX2.5 and troponin C shows
that the percentage of NKX2.5 expressing cells is lower than
that of cells expressing troponin C for both cell populations,
with the percentages of cells expressing troponin C being
higher in all cases for CMSCLC (98%, 99%, and 84%)
compared with CDCs (86%, 68%, and 63%) (Fig. 6I).
Molecular analysis was used to examine the undifferenti-
ated CMSCLC and after culture under cardiac differentiation
conditions for expression of genes important for cardiogen-
esis, both populations expressed MEF2C and GATA4 (Sup-
plementary Fig. S5).
Single-cell transcriptomic analysis
We examined CMSCLC derived from three patients; only
cells that passed the quality control steps (see the Materials
and Methods section) were included in the downstream
analysis. The percentage of genes being expressed by cells
in each culture was calculated (Fig. 7). B-actin was used as a
housekeeping gene and was expressed by all cells. CD44
and tropomyosin were also expressed by all the cells ana-
lyzed. GATA4 (percentage of cells expressing ranging from
82.5% to 100%), VEGF (percentage of cells expressing
ranging from 97.8% to 100%), and TGF-b (percentage of
cells expressing ranging from 96.5% to 100%) were also
highly expressed. CDC73 was more variable, being ex-
pressed by 100% of the cells in one culture and by 95.6%
and 79.3% of cells in the other two cultures. The expression
FIG. 5. Quantification of CMSCLC p16 immunostaining. Representative image of p16 ICC showing results of staining of
CMSCLC from patients, 1179, p16 (green), all nuclei stained with DAPI (blue), scale bar= 100mm (A). CMSCLC cultures
derived from three different patient tissue samples were immunostained for the cell senescence marker p16 and counter-
stained with DAPI. The percentage of p16-positive cells within each culture was calculated by counting five independent
fields within each culture. Box-plot analysis (SPSS) showed no significant difference in p16 expression between n = 3
patient cultures (B). Color images are available online.
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FIG. 6. Characterization of cardiac differentiation potential of CDCs and CMSCLC. Representative images of CDC (n= 3
donors) and CMSCLC (n= 4) donors at 14 days under cardiac differentiation culture conditions show that some of both
CDC (A) and (B) CMSCLC differentiated cells have a more mature cardiac morphology and express troponin C (green-
Alexa Fluor 488). While other cells from the same patient samples cultured under the same conditions but stained for
expression of NKX2.5 have a more primitive rounded morphology and express nuclear NKX2.5 (NKX2.5 green-Alexa
Fluor 488) in differentiated CDC (C) and differentiated CMSCLC culture (D). White arrows in (C, D) indicate cells shown
in inserts of NKX2.5 staining without the DAPI overlay to shown the nuclear localization of NKX2.5. (E–H) Re-
presentative images of CMSCLC (n = 4 donors) differentiated for 3 weeks and analyzed by confocal microscopy. (E)
Maximum intensity projections of differentiated CMSCLC expressing troponin C (green-Alexa Fluor 488). (Ei) Higher
magnification image demonstrates early striations, indicated by yellow arrow. (F) Maximum intensity volume projection of
differentiated CMSCLC labeled with cardiac actin (red-Alexa Fluor 594). (G) Maximum intensity volume projection of
differentiated CMSCLC labeled with alpha-tropomyosin (red-Alexa Fluor 594). (H, Hi) Maximum intensity volume pro-
jection demonstrates striated pattern of alpha-tropomyosin expression, indicated by yellow arrows. For all images, nuclei
labeled with DAPI-blue. Scale bars were either 20 or 50 mm as indicated. (I) Bar chart showing percentage of cells
expressing NXK2.5 or troponin C, n = 3 for both CDC and CMSCLC cultures analyzed. Color images are available online.
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of FGF-2 (100, 56.5, and 62%), HGF (18.5%, 89.1%,
41.3%), PCNA (98.5%, 71.7%, 55.1%), MEF2 (81.5%,
86.9%, 31%), and MCAM (58.4%, 32.6%, 27.5%) also
varied between the different donor cultures. c-Kit expression
was also variable between the different donor-derived cul-
tures with percentage of cells expressing being 3% and
10.8%, and with one culture having no detectable expression
(Fig. 7). No expression was observed for NXK.25 in any of
the cells of the three donor cultures analyzed (data not
shown).
Discussion
The International Society for Cell Therapy position arti-
cle (2006) set the minimum requirements for cells to be
considered MSCs as follows: the ability to adhere to plastic
under standard culture conditions, to express a number of
cell surface antigens, to lack expression of a number of
markers, including the hematopoietic lineage markers CD45
and CD19, and to differentiate to osteoblasts, adipocytes,
and chondroblasts in culture [18]. This article included the
caveat that these criteria would need modification as our
knowledge of MSCs increased. MSCs also have distinct cell
morphology in vitro displaying a fibroblast-like morphology
with cells showing parallel alignment and tapering of the
fibroblast-like cellular protrusions [19]. CMSCLC displayed
some of these characteristics, being plastic adherent in MSC
culture conditions, having an MSC-like morphology, and
expressing MSC markers CD105, CD166, and CD44 [20].
CMSCLC differed from CS-CDCs, displaying higher levels
of expression of these antigens. Although controversial,
human MSCs have been reported as being MHC I positive
and having low/no expression of MHC II [21]. CDCs also
express MHC I and lack expression of MHC II [22], and
CMSCLC express MHC I and have low expression of MHC
II. MSCs have been reported to have immunomodulatory
properties, in part, due to their ability to secrete the anti-
inflammatory cytokine IL10, which has been suggested to be
cardiobeneficial. In a rat model of myocardial infarction,
transplanted MSCs help reduce the inflammatory response
and this was, in part, due to increased levels of IL10 [23].
We examined CMSCLC for IL10 expression and observed
increased expression when cells where cultured for 14–
17 days. In contrast to CS-CDCs, CMSCLC were unable to
differentiate to the osteogenic lineage as they exhibit little/
no matrix mineralization as indicated by the low/absence of
alizarin red staining, while all CS-CDCs stained strongly
for alizarin red. However, both cell populations exhibited
low adipogenic differentiation and both failed to undergo
chondrogenesis. This contrasts with BM-MSCs and sub-
endocardial MSCs that have this trilineage differentiation
potential [9]. These differences might be due to these being
distinct cell populations, differences in tissue used for cell
derivation (subendocardial MSCs are derived from ventri-
cle, while CMSCLC are derived from atrial tissue), or due
to differences in culture conditions used. CDCs and sub-
endocardial MSCs are grown out from tissue explants,
whereas CMSCLC are derived from single-cell suspen-
sions and CMSCLC are cultured in 5% CO2, 5% O2,
whereas no information is provided on the oxygen condi-
tions for the culture of subendocardial MSCs. We have re-
ported on increased derivation rates, osteogenic potential,
and cellular health of MSCs derived from hemarthrosis fluid
cultured under low oxygen conditions versus those cultured
under standard conditions [14], supporting the hypothesis
that culture conditions may influence cell behavior or pos-
sibly support the preferential selection of a subset of cells
within a heterogeneous cell population. Certain cardiac stem/
progenitor cells have been shown to be preferentially located
in distinct anatomical regions of the heart, for example, adult
human cardiac side population cells have been reported to be
confined to the left atrium and absent from the right [24]. In a
molecular study of multiple mouse cardiac stem cell popu-
lations, a comparison was made between the mouse data and
microarray data available in the public domain and CS-
CDCs appeared to be closely related to BM-MSCs [25]. This
might also account for the osteogenic response displayed by
our CS-CDCs. In addition, subendocardial MSCs were re-
ported as being strongly positive for c-kit expression [9] and
human CS-CDCs have been reported to express c-kit (about
18% of the total cell population) [26], while CMSCLC
showed only low-level expression of c-kit. Identification of
cardiac stem cells based on expression of c-kit alone has
been brought into question. However, in a recent study, it has
been reported that within the CD45negc-kitpos cells found in
the heart, a small subpopulation of between 1% and 2% have
the characteristics of true multipotent cardiac stem cells [17].
Therefore, the small percentage of c-kit expressing cells
FIG. 7. Graphical representation
of single-cell data representing
percentage of CMSCLC expressing
genes of interest for n= 3 donors.
The percentage of cell expressing
each gene is shown. Color images
are available online.
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observed in CMSCLC cultures could represent such a pop-
ulation. The CMSCLC containing the highest percentage of
c-kit expressing cells (2.6%) was also the only culture con-
taining NkX2.5 expressing cells. PDGFR-alpha has been
reported to be expressed by progenitor cells in human fetal
and diseased adult heart [27]. Therefore, we also examined
CMSCLC and observed that some expressed PDGFR-alpha.
CMSCLC displayed other stem cell characteristics, in-
cluding the ability to form CFUs and be expanded in vitro.
All CMSCLC cultures had similar potential with regard to
cell doubling rates, while rates for CS-CDCs have been
reported to be similar for cells generated from both non-
transplant heart failure and transplant heart patient’s biopsy
specimens [26]. Under cardiac differentiation culture con-
ditions, both CS-CDC and CMSCLC had a phenotype pre-
viously reported for cardiomyocytes in culture [28].
Moreover, in these conditions, all CS-CDC cultures, but
only one CMSCLC culture, also contained a population of
cells that expressed nuclear NXK2.5 and had an immature
rounded morphology. These characteristics have previously
been suggested to be indicative of a more primitive or early
cardiac committed cell [29] and may suggest that the CS-
CDCs are more heterogeneous than the CMSCLC or that the
CMSCLC are more mature. This is further supported by our
quantification of cells expressing troponin C, showing all
CMSCLC containing higher numbers of troponin C ex-
pressing cells than CS-CDCs. In addition, we also observed
that undifferentiated and differentiated CMSCLC expressed
genes important for myocardial lineage development, in-
cluding MEF2C and GATA4 [30,31]. Atrial appendage-
derived cardiac stem cells also express markers important
for myocardial development and even postinduction of
differentiation to a more mature cardiac lineage, they con-
tinue to express MEF2C and GATA4 [32]. It is recognized
that for MSCs derived from patient tissue, patient to patient
variability does exist [33], and this could be responsible for
the difference in the presence/absence of the NXK2.5 ex-
pressing cells in the CMSCLC cultures.
If cardiac stem/progenitors are to be used as a cellular
therapy or indicator of heart health, the level of cellular
senescence needs to be determined. We examined CMSCLC
derived from three different donors at passage 3 and ob-
served the presence of between 5% to 15% senescent cells.
Whether the presence of senescent cells within CMSCLC
would prove to be a problem in utilizing these as a cellular
therapy would need to be further explored. CSC expanded
over *113 days have been shown to contain small per-
centages of senescent cells (however, the authors of this
study did not provide data on % observed) and yet still
deemed suitable for intracoronary perfusion in patients with
heart failure [1].
Human cardiac atrial appendage stem cells (CASCs), like
CMSCLC, also fail to differentiate toward the osteogenic
lineage. However, unlike the CMSCLC, they also failed to
differentiate toward the adipogenic lineage [34]. CASCs
also lack expression of c-kit and CD44 [34], while most of
our CMSCLC cultures contain small numbers of c-kit+ cells
and express CD44. It is interesting to note that both atrial
appendages can be used as a source of stem cells. Why the
atrial appendages are such good sources of stem cells is not
entirely understood, but they have a distinct developmental
origin to the atria and display many trabeculae similar to
ventricles [10]. They are also a source of atrial natriuretic
peptide factor (ANP). Nppa, the gene encoding ANP, has
been shown to be important for heart development as well as
being reactivated in adult disease [35]. It may be that these
developmental/fetal links make the appendages such rich
sources of stem cells. A study of mouse left atrial appendage
showed it to be a source of more than one type of cardiac
progenitor population [36].
As a cellular therapeutic, RAA-derived CMSCLC might
have advantages over subendocardial-derived MSCs (that
readily differentiate to osteogenic, adipogenic, and chon-
drogenic lineages, but remain primitive under cardiac dif-
ferentiation conditions) and CS-CDCs or BM-MSCs as they
lack the osteogenic potential of the former and the osteo-
genic and chondrogenic potential of the latter. This may
have important implications for the use of CMSCLC as a
potential cellular therapeutic as they could be less likely to
contribute to cardiac calcification. The cause of this remains
controversial, and while there is no evidence from clinical
trials to date that cardiac-derived cell transplantation causes
calcification, there is evidence that cells with osteogenic and
chondrogenic differentiation potential may be involved [37].
CMSCLC also differ from CS-CDCs as they do not require
the rounds of harvesting/replating required to generate CS-
CDCs [25].
We did not observe spontaneous beating of CMSCLC
under cardiac differentiation conditions; this may be a
limitation of the technique used. Human CS-CDCs also
failed to beat in vitro unless cocultured with neonatal rat
ventricular myocytes [26], this was also the case with hu-
man CASCs [34].
Our single-cell analysis demonstrated that 100% of
CMSCLC expressed CD44, a recognized marker of MSCs
[19]. A large percentage of CMSCLC also expressed CDC73,
which is associated with stem cell pluripotency [38]. Our
single-cell analysis also supported our standard PCR analysis
showing that GATA4 and MEF2 were also detectable at the
single-cell level. GATA4 was expressed by all CMSCLC for
all three donors (100%, 84.7%, and 82.5%), while MEF2C
expression was more variable with two cultures having high
numbers of MEF2C-positive cells (86.9% and 81.5%), but in
the third only 31%. One hundred percentage of CMSCLC
expressed tropomyosin and 98.5%, 71.7%, and 55% of
CMSCLC expressed PCNA and nearly all expressed VEGF.
Lower numbers of CMSCLC expressed MCAM (also known
as CD146) with percentages varying from the highest at
58.4% to the lowest at 27.5%. CD146 has been reported to be
expressed by a subpopulation of human MSCs from a telo-
merized bone marrow-derived stromal cell line [39]. While in
the heart, it has been reported to be a marker of perivascular
mesenchymal precursor cells [40]. Together, these data sug-
gest that CMSCLC are proliferative, pluripotent, and have
some multilineage differentiation potential compared with
other cells important in the heart. It also supports our in vitro
culture observation of some CMSCLC being capable of ex-
pressing the endothelial cell marker CD34 under EC differ-
entiation conditions. CMSCLC for all donors also expressed
TGF-b. The role of TGF-b in the heart remains controversial;
it has been reported to contribute to heart failure, but has also
been suggested to be important for suppression of inflam-
mation following myocardial infarction and been reported to
be cardioprotective [41,42]. CMSCLC also expressed VEGF
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(97.8%–100%), FGF2 (56.6%, 62.0%, and 100%), and HGF
(18.0%, 41.3%, and 89.1%), which have all been reported to
be cardioprotective/cardiobeneficial [42–44]. We also dem-
onstrated using CMSCLC-conditioned media that CMSCLC
secrete a number of potentially cardiobeneficial factors, in-
cluding IL10, VEGF, FGF2, and TGFb1. The role of MSC
paracrine-secreted factors that have protective/regenerative
effects has now been demonstrated in several different tis-
sues. In a rat neonatal hyperoxic lung injury model, human
umbilical cord blood MSCs that secrete VEGF improved the
survival rates on rat lung epithelial cells treated with hydro-
gen peroxide; to confirm this protective effect, these cells
were then used in an in vivo model of hyperoxic injury where
it was again shown that the VEGF secreting MSCs protected
against hyperoxia [45]. In a rat model of liver regeneration,
BM-MSCs alone or transfected with the VEGF gene were
injected into the liver after a major hepatic resection; both
groups of cells engrafted into the liver were they secreted a
number of paracrine factors, including VEGF, FGF, TGFb,
and HGF, and in both cases, bile duct and liver hepatocyte
proliferation occurred [46]. The paracrine activity of MSCs
may be multimodal as they have also been reported to be able
to cause cardiomyocyte proliferation, be immunomodulatory,
and activate resident cardiac stem cells spared by cardiac
injury [reviewed in Ref. 47]. In addition, single-cell analysis
showed only a few CMSCLC expressed c-kit, data that sup-
port the low percentages of c-kit expressing cells observed in
the CMSCLC using FACS. Single-cell profiling as a means of
determining the paracrine activity of MSCs has previously
been used successfully in a study on the role of MSCs in an
infracted mouse heart, where the authors showed using a
single-cell approach that MSCs transplanted into injured heart
expressed paracrine factors in vivo [48].
We have shown that CMSCLC cultured under cardiac
differentiation conditions display morphology and expressed
some markers of more mature cardiac lineage-committed
cells, even showing early striation formation. Similar changes
have been observed in rat CDCs differentiated to a more
mature cardiac lineage in vitro [49]. In addition, CMSCLC
secrete cardiobeneficial factors and have low/no adipo-
genic, chondrogenic, or osteogenic differentiation poten-
tial, all qualities that should be advantageous for cells to be
used therapeutically for cardiac regeneration.
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